Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Pabst

Showing results (251-260 of 332) with videos related to

Pageof 34
Sort By:
Leukemia|March 24, 2026
CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic targetStefan Forster, Chantal Reinhardt, Maxime Boy, et al.
Bone Marrow Transplantation|November 4, 2018
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry studyGuido Ghilardi, Thomas Pabst, Barbara Jeker, et al.
Annals of Hematology|March 11, 2021
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohortMagdalena M Brune, Georg Stüssi, Pontus Lundberg, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|June 26, 2022
Development of a Score for Prediction of Occult Malignancy in Stroke Patients (Occult-5 Score)Morin Beyeler, Barbara Birner, Mattia Branca, et al.
Nature Medicine|July 1, 2020
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agentsCarsten Riether, Thomas Pabst, Sabine Höpner, et al.
Frontiers in Neurology|October 16, 2023
Transient ischemic attacks in patients with active and occult cancerMorin Beyeler, Pasquale Castigliego, Joel Baumann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trialHans Theodor Eich, Volker Diehl, Helen Görgen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 1, 2026
Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysisSophie Wollnitza, David Ventura, Marcel Teichert, et al.
The New England Journal of Medicine|September 25, 2009
High-dose daunorubicin in older patients with acute myeloid leukemiaBob Löwenberg, Gert J Ossenkoppele, Wim van Putten, et al.
Trials|October 1, 2020
Application of two different nasal CPAP levels for the treatment of respiratory distress syndrome in preterm infants-"The OPTTIMMAL-Trial"-Optimizing PEEP To The IMMAture Lungs: study protocol of a randomized controlled trialMarkus Waitz, Corinna Engel, Rolf Schloesser, et al.
Pageof 34

Showing results (251-260 of 332) with videos related to

Sort By:
Pageof 34
Leukemia|March 24, 2026
CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic targetStefan Forster, Chantal Reinhardt, Maxime Boy, et al.
Bone Marrow Transplantation|November 4, 2018
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry studyGuido Ghilardi, Thomas Pabst, Barbara Jeker, et al.
Annals of Hematology|March 11, 2021
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohortMagdalena M Brune, Georg Stüssi, Pontus Lundberg, et al.
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|June 26, 2022
Development of a Score for Prediction of Occult Malignancy in Stroke Patients (Occult-5 Score)Morin Beyeler, Barbara Birner, Mattia Branca, et al.
Nature Medicine|July 1, 2020
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agentsCarsten Riether, Thomas Pabst, Sabine Höpner, et al.
Frontiers in Neurology|October 16, 2023
Transient ischemic attacks in patients with active and occult cancerMorin Beyeler, Pasquale Castigliego, Joel Baumann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trialHans Theodor Eich, Volker Diehl, Helen Görgen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 1, 2026
Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysisSophie Wollnitza, David Ventura, Marcel Teichert, et al.
The New England Journal of Medicine|September 25, 2009
High-dose daunorubicin in older patients with acute myeloid leukemiaBob Löwenberg, Gert J Ossenkoppele, Wim van Putten, et al.
Trials|October 1, 2020
Application of two different nasal CPAP levels for the treatment of respiratory distress syndrome in preterm infants-"The OPTTIMMAL-Trial"-Optimizing PEEP To The IMMAture Lungs: study protocol of a randomized controlled trialMarkus Waitz, Corinna Engel, Rolf Schloesser, et al.
Pageof 34